Join Growin Stock Community!

Clene inc.CLNN.US Overview

US StockHealthcare
(No presentation for CLNN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CLNN AI Insights

CLNN Overall Performance

CLNN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CLNN Recent Performance

-4.11%

Clene inc.

0.05%

Avg of Sector

-0.31%

S&P500

CLNN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CLNN Key Information

CLNN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CLNN Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Price of CLNN

CLNN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CLNN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
287.58
PB Ratio
7.83
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
82.24%
Net Margin
-14250.47%
Revenue Growth (YoY)
-49.17%
Profit Growth (YoY)
-46.83%
3-Year Revenue Growth
-55.82%
3-Year Profit Growth
-54.09%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
287.58
PB Ratio
7.83
Price-to-FCF
-
Gross Margin
82.24%
Net Margin
-14250.47%
Revenue Growth (YoY)
-49.17%
Profit Growth (YoY)
-46.83%
3-Year Revenue Growth
-55.82%
3-Year Profit Growth
-54.09%

  • When is CLNN's latest earnings report released?

    The most recent financial report for Clene inc. (CLNN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CLNN's short-term business performance and financial health. For the latest updates on CLNN's earnings releases, visit this page regularly.

  • What is the operating profit of CLNN?

    According to the latest financial report, Clene inc. (CLNN) reported an Operating Profit of -5.65M with an Operating Margin of -37,653.33% this period, representing a growth of 27.73% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CLNN's revenue growth?

    In the latest financial report, Clene inc. (CLNN) announced revenue of 15K, with a Year-Over-Year growth rate of -82.76%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CLNN have?

    As of the end of the reporting period, Clene inc. (CLNN) had total debt of 21.31M, with a debt ratio of 0.96. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CLNN have?

    At the end of the period, Clene inc. (CLNN) held Total Cash and Cash Equivalents of 7.98M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CLNN go with three margins increasing?

    In the latest report, Clene inc. (CLNN) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -37,653.33%%, and net margin of -58,513.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CLNN's profit trajectory and future growth potential.

  • Is CLNN's EPS continuing to grow?

    According to the past four quarterly reports, Clene inc. (CLNN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CLNN?

    Clene inc. (CLNN)'s Free Cash Flow (FCF) for the period is -4M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 32.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.